<DOC>
	<DOCNO>NCT02745184</DOCNO>
	<brief_summary>Idiopathic pulmonary fibrosis ( IPF ) chronic ultimately fatal disease characterize progressive damage lung structure decline lung function.This study intend carry open , single-center , non-randomized , self control phase I clinical trial . During treatment , lung stem cell isolated patient ' bronchus expand vitro . Cultured cell inject directly lesion fiberoptic bronchoscopy lavage . After twelve-month observation , investigator evaluate safety efficacy treatment measure key clinical indicator .</brief_summary>
	<brief_title>Clinical Efficacy Safety Autologous Lung Stem Cell Transplantation Patients With Idiopathic Pulmonary Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>1 ) Written informed consent sign ; 2 ) 40 &lt; Age &lt; =75 year ; 3 ) Clinically diagnose idiopathic pulmonary fibrosis ( see 2011 guidance ) ; 1 . Allergic cell therapy ; 2 . Patients serious significant pulmonary infection need antiinfection treatment ; 3 . Patients take amiodarone may cause pulmonary fibrosis past 3 month ; 4 . Patients malignant tumor past 5 year ; 5 . Participated clinical trial past 3 month ; 6 . Patients serious heart disease ( NYHA class ⅢⅣ ) , liver disease ( ALT AST 2 time upper level normal value range ) , kidney disease ( Cr upper level normal value range ) ; 7 . Pregnant lactating woman ; 8 . The investigator assess inappropriate participate clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>